




Science For A Better Life


HealthCare CropScience MaterialScience

Bayer R&D Investor Day 2005

December 8, 2005 | London



Bayer



Bayer R&D Investor Day 2005

Summary of the Day

Werner Wenning
CEO
Bayer AG

Bayer R&D Investor Day • London • December 8, 2005 • Werner Wenning • Summary • Page 2

Forward Looking Statements



This presentation contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management.

Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Summary Pharmaceuticals



- Alignment of Pharma R&D successfully executed
- NSCLC as additional opportunity increases the peak sales potential of Nexavar to more than € 1 billion
- Factor Xa inhibitor on track to initiate Phase III in VTE prevention with once-daily dosing and Phase III in chronic indications in first half 2006
- Promising clinical projects beyond Nexavar and Factor Xa-inhibitor –
At least three Phase II transitions expected in 2006
- Life-cycle innovations are driving the peak sales potential of Kogenate beyond € 1 billion and of Trasylol beyond € 500 million

A pipeline that has the potential to transform our Pharma business

Summary CropScience



- R&D focused on identification of new active ingredients, the optimization of the existing portfolio and plant biotechnology
- 10 new active ingredients scheduled for launch between 2006 and 2011
- Prothioconazole based products have a combined peak sales potential of more than € 300 million
- Peak sales potential of products launched between 2000 and 2011 estimated at approx. € 2 billion
- Bayer continues to develop superior plant biotechnology solutions

We are committed to remain the innovation leader in crop protection solutions

Summary MaterialScience



- More than 20% of 2004 sales achieved with new products
- Bayer is well positioned in the growing markets for new polymer applications in automotive and electro/electronics
- Continuous innovations make Bayer's polycarbonate a resin of choice for present and future applications in optical data storage
- Technological breakthrough achieved in polycarbonate for automotive glazing
- Bayer has the capability to set new standards for world-scale and process efficiency

New products will continue to drive sales growth

We are defending our position as technology leader in PCS and PUR



- Achieving or exceeding committed objectives
- Exploiting the commercial potential of leadership positions
- Developing future growth opportunities
- Generating value for our shareholders

Bayer R&D Investor Day • London • December 8, 2005 • Werner Wenning • Summary • Page 7



Science For A Better Life

HealthCare

CropScience

MaterialScience

Bayer R&D Investor Day 2005

December 8, 2005 | London